Intraocular Lenses and Corneal Collagen Crosslinking Research
- Emory Eye Center is among the first to offer a newly FDA-approved multi-focal intraocular lens (IOL) for cataract patients. IOL is a plastic implant that is used to replace the natural lens of the eye, providing patients freedom from glasses, as well as near, intermediate and far vision capabilities.
The Emory Eye Center is at the forefront of major developments in ophthalmology research, and is currently researching a new technology called corneal collagen crosslinking with Riboflavin (CXL). This is an experimental treatment which stiffens the cornea and treats two eye conditions: keratoconus and ectasia. This treatment has the promise of stopping the progression of keratoconus, in which currently, there is no medical treatment and is responsible for 15 percent of corneal transplants in the United States (for more information).
Patient Advantages:
- The AcrySof® ReSTOR lens, a foldable IOL that replaces diseased cataracts, provides high-quality distance and near vision for cataract patients, and significantly reduces an individual's dependency on glasses.
- The new lens allows some patients freedom from glasses immediately following their IOL implants.
- The procedure restores vision to cataract surgery patients — patients usually have driving vision within 15 minutes of the procedure and go back to their normal activities the following day.
